Intravesical chemotherapy

膀胱内化疗
  • 文章类型: Case Reports
    膀胱癌肉瘤或肉瘤样癌是一种罕见但侵袭性的膀胱癌,其特征是恶性上皮和间质成分。到目前为止,文献中只报道了少数病例。在这份报告中,我们讨论了一例74岁女性非吸烟者,该患者在过去4个月内出现间歇性血尿和血块通过.X线图像显示膀胱左侧壁靠近膀胱输尿管连接处的不规则肿块(6.2x6cm)。通过经尿道膀胱肿瘤切除术(TUR-BT)将肿块完全切除。组织病理学研究显示高级别癌肉瘤,免疫组织化学显示波形蛋白弥漫性阳性,泛细胞角蛋白(CK)和CK7,上皮膜抗原(EMA),CK5/6患者拒绝根治性膀胱切除术,只同意接受膀胱内化疗(吉西他滨),经过四年多的随访,她仍然活着。膀胱癌肉瘤是一种罕见的肿瘤,主要影响老年人,最常见的是根治性膀胱切除术和不同的联合治疗方法,如化疗和放疗。然而,肿瘤切除后膀胱灌注化疗可能是一些患者早期膀胱癌肉瘤的替代选择,从而避免了积极治疗的需要,特别是对于拒绝接受根治性手术的老年患者。
    Carcinosarcoma or sarcomatoid carcinoma of the urinary bladder is a rare but aggressive bladder cancer characterized by malignant epithelial and mesenchymal components, with only a few cases reported in the literature so far. In this report, we discuss a case of a 74-year-old female nonsmoker who presented with intermittent hematuria and passage of clots in the last four months. Radiographic images showed an irregular mass lesion (6.2 x 6 cm) in the left lateral wall of the urinary bladder near to left vesicoureteral junction. The mass was completely removed with transurethral resection of the bladder tumor (TUR-BT). Histopathological study revealed high-grade carcinosarcoma, and immunohistochemistry showed diffuse positivity for vimentin, pan-cytokeratin (CK) and CK7, epithelial membrane antigen (EMA), and CK5/6. The patient declined radical cystectomy and only agreed to receive intravesical chemotherapy (gemcitabine), and she remains alive after more than four years of follow-up. Carcinosarcoma of the urinary bladder is a rare tumor primarily affecting older people, and it is most commonly treated with radical cystectomy and different combination treatments such as chemotherapy and radiation. However, tumor resection followed by intravesical chemotherapy may be an alternative option in the early stages of bladder carcinosarcoma for some patients, thereby avoiding the need for aggressive treatments, especially for elderly patients who decline to undergo radical surgery.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    肿瘤切除后立即膀胱内化疗滴注是治疗非肌层浸润性膀胱癌的众所周知的做法。尽管在大多数情况下耐受性良好,它并非没有严重和危及生命的并发症。
    我们介绍了一例膀胱肿瘤切除2周后发生的膀胱穿孔的罕见病例。患者在TUR-BT后接受了单剂量膀胱内滴注阿霉素。保守治疗未能实现膀胱愈合;结果,进行了开放手术修复。据我们所知,这是首次报道膀胱内阿霉素滴注后膀胱穿孔病例.
    在最安全的干预措施中,必须考虑到这种罕见的严重并发症的发生。高度怀疑,及时管理,并在必要时进行更具侵入性的手术治疗是管理和保留膀胱的基石。
    UNASSIGNED: Intravesical chemotherapy instillation immediately after tumor resection is a well-known practice in the management of non-muscle invasive bladder cancer. Despite being largely well tolerated in most cases, it is not devoid of severe and life-threatening complications.
    UNASSIGNED: We present an unusual case of bladder perforation that happened 2 weeks after bladder tumor resection. The patient had received single dose intra-vesical instillation of doxorubicin after TUR-BT. Conservative managements failed to achieve bladder healing; as a result, open surgical repair was performed. To the best of our knowledge, this is the first reported case of bladder perforation after intra-vesical doxorubicin instillation.
    UNASSIGNED: The occurrence of such a rare serious complication in a mostly safe intervention must be taken into consideration. A high index of suspicion, timely management, and proceeding to more invasive surgical treatments when necessary are cornerstones in the management and preserving the bladder.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Case Reports
    背景:原发性尿道癌极为罕见,导致临床医生的经验受到限制,而准确的诊断往往因非特异性临床表现而延迟。这里,我们提供此病例报告,以显示一名原发性尿道癌患者的治疗方法。我们的患者在宜昌市第一临床医院通过膀胱镜检查和活检被诊断为原发性尿道癌。由于她的年龄,身体耐受性差,和经济状况,她拒绝了激进的手术。由于临床上对原发性尿道癌的治疗过程没有明确的指导,不同医院的手术方法和术后辅助治疗各不相同,导致不同的预后效果。
    方法:一名88岁的亚洲女性排尿困难超过6个月,症状加重1个月。她选择了较为守旧的医治计划:原发肿瘤切除联合膀胱灌注化疗。术后病理显示“尿道”高级别尿路上皮癌(肉瘤样变种)伴广泛坏死。用膀胱内化疗药物(羟基喜树碱40mg)治疗后,她最终从我们医院出院,情况稳定。术后随访观察该保守治疗方案在多大程度上改善了患者的生活质量和总体生存时间。
    结论:根据实际情况需要进行根治性切除。然而,她的年龄限制了她对全身麻醉的耐受性;相对保守的治疗方案可确保高质量的生活.原发肿瘤切除联合膀胱灌注化疗的医治是可行的。该病例强调了传播新病例和优化原发性尿道癌诊断以获得有效治疗的重要性。
    BACKGROUND: Primary urethral cancer is exceedingly rare, resulting in a limitation in clinicians\' experience, and an accurate diagnosis is often delayed due to the non-specific clinical presentation. Here, we present this case report to show the treatment of a patient with primary urethral cancer. Our patient was diagnosed as having primary urethral cancer in the First Clinical Hospital of Yichang by cystoscopy and biopsy. Due to her age, poor physical tolerance, and economic condition, she refused radical operation. Since there is no definite guideline for the treatment process of primary urethral cancer in clinics, operation methods and postoperative adjuvant treatments vary in different hospitals, leading to diverse prognostic effects.
    METHODS: An 88-year-old Asian woman had difficulty in urinating for more than 6 months and the syndrome was aggravated for 1 month. She chose a relatively conservative treatment plan: primary tumor resection combined with bladder perfusion chemotherapy. Postoperative pathology revealed \"urethra\" high-grade urothelial carcinoma (sarcoma-like variants) with extensive necrosis. After treatment with intravesical chemotherapeutic drug (hydroxycamptothecin 40 mg), she was eventually released from our hospital in a stable condition. Postoperation follow-up was performed to observe to what extent this conservative treatment plan improved the quality of life and overall survival time of our patient.
    CONCLUSIONS: She needed radical resection according to the actual situation. However, her age restricted her tolerance to general anesthesia; relatively conservative treatment options are available to ensure a high quality of life. The treatment of primary tumor resection combined with bladder perfusion chemotherapy is feasible. This case highlights the importance of the dissemination of new cases and optimizing primary urethral cancer diagnosis to obtain an effective treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号